Actuate Therapeutics, Inc. Common stock Market Cap ($7.95 Million)
Market Cap & Net Worth: Actuate Therapeutics, Inc. Common stock (ACTU)
Actuate Therapeutics, Inc. Common stock market cap. Actuate Therapeutics, Inc. Common stock (NASDAQ:ACTU) has a market capitalization of $7.95 Million ($7.95 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27499 globally and #5700 in its home market, demonstrating a -28.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Actuate Therapeutics, Inc. Common stock's stock price $0.34 by its total outstanding shares 23243328 (23.24 Million). Also see cash efficiency ratio of Actuate Therapeutics, Inc. Common stock for how efficiently the company converts equity into cash flow.
Actuate Therapeutics, Inc. Common stock Market Cap History (2024–2026)
Actuate Therapeutics, Inc. Common stock market cap history from 2024 to 2026. Data shows change from $185.02 Million to $7.95 Million (-76.59% CAGR). Check Actuate Therapeutics, Inc. Common stock stock quote for real-time trading data and today's change.
Index Memberships
Actuate Therapeutics, Inc. Common stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #776 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2520 of 3165 |
Weight: Actuate Therapeutics, Inc. Common stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Actuate Therapeutics, Inc. Common stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Actuate Therapeutics, Inc. Common stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Actuate Therapeutics, Inc. Common stock to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ACTU by Market Capitalization
Companies near Actuate Therapeutics, Inc. Common stock in the global market cap rankings as of November 4, 2026. Also see Actuate Therapeutics, Inc. Common stock total assets for a full breakdown of the balance sheet.
Key companies related to Actuate Therapeutics, Inc. Common stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Actuate Therapeutics, Inc. Common stock (2024–2026)
Market capitalization of Actuate Therapeutics, Inc. Common stock from 2024 to today. Between 2024 and today, Actuate Therapeutics, Inc. Common stock's market cap moved from $185.02 Million to $ 7.95 Million, with a yearly change of -76.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.95 Million | -94.41% |
| 2025 | $142.25 Million | -23.12% |
| 2024 | $185.02 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Actuate Therapeutics, Inc. Common stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.95 Million USD |
| MoneyControl | $7.95 Million USD |
| MarketWatch | $7.95 Million USD |
| marketcap.company | $7.95 Million USD |
| Reuters | $7.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of… Read more